Abstract 1577P
Background
Antibiotic therapy has been known to disrupt microbiota homeostasis and systemic immune responses, both of which are linked to response to immune checkpoint blockade. We aim to investigate whether prior antibiotics (pATB) administration influences outcomes following treatment with programmed cell death protein-1 (PD-1) inhibitors or chemotherapy in patients with advanced gastric cancer (AGC).
Methods
We analysed data of patients with AGC who were treated with PD-1 inhibitors (retrospective exploratory cohort; n=152) or irinotecan (chemotherapy cohort; n=101). Patients were classified into two groups based on whether they had received pATB within 28 days prior to the treatment. Another independent retrospective validation cohort (n=123) and prospective validation cohort (n=30) treated with PD-1 inhibitors were further analysed. Distinct features in gut microbiome and circulating immune cells were analysed (experimental cohort; n=24).
Results
In the retrospective exploratory cohort, pATB administration was associated with poor 17 progression-free survival (PFS; hazard ratio [HR]=2.897, 95% confidence interval [CI]=2.043–4.109) and overall survival (OS; HR=2.294, 95% CI=1.622–3.242) but did not affect outcomes among patients treated with irinotecan. In the validation cohorts, pATB administration was associated with poor treatment outcomes following PD-1 blockade. Multivariate analysis of the overall patients treated with PD-1 inhibitors confirmed that pATB was an independent predictor of poor PFS (HR=3.243, 95% CI=2.427–4.333) and OS (HR=3.046, 95% CI= 2.358–3.935). Administration of pATB was associated with diminished gut microbiome diversity, reduced abundance of Lactobacillus gasseri, and disproportional enrichment of circulating exhaustive CD8+ T cells, all of which can hinder the efficacy of PD-1 blockade.
Conclusions
Considering the inferior treatment response and poor survival outcomes by pATB followed by PD-1 blockade, antibiotics should be prescribed with caution in patients with AGC planned to receive PD-1 inhibitors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Research Foundation of Korea, Ministry of Science and ICT, Yonsei University College of Medicine.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1569P - The CODRP model for predicting drug sensitivity in patient-derived 3D gastric cancer cells
Presenter: Dong Woo Lee
Session: Poster session 22
1571P - Exploration of immune and metabolism gene signature for prognosis of esophageal carcinoma and establishment of a combined prediction model
Presenter: Hao Wu
Session: Poster session 22
1572P - Impact of HER2 and PD-L1 co-expression in Claudin18.2 positive resectable gastroesophageal cancers
Presenter: Antonella Cammarota
Session: Poster session 22
1573P - Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC
Presenter: Baosheng Li
Session: Poster session 22
1575P - Factors associated with uptake of adjuvant nivolumab in a nationwide esophageal cancer patient cohort
Presenter: Rob Verhoeven
Session: Poster session 22
1578P - Effect of immune checkpoint inhibitors in metastatic gastric cancer: A real-world evidence study
Presenter: Francesco Puccetti
Session: Poster session 22
1579P - Gender differences and worse metastatic survival outcomes in young adult patients with oesophagogastric cancer: 12-year data from a Czech comprehensive cancer center
Presenter: Tomás Sokop
Session: Poster session 22